Navigation Links
Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled its first subjects in its once-daily topical diclofenac sodium patch Phase III program. The program consists of three randomized, double-blind, placebo-controlled Phase III clinical studies with Cerimon's diclofenac patch. The studies will assess the efficacy and safety of Cerimon's diclofenac patch compared to placebo for the treatment of acute pain caused by mild-to-moderate ankle sprains, wrist injuries and soft tissue injuries of the upper and lower extremities. The ankle sprain and wrist injury studies will each enroll 208 subjects, and the soft tissue injury study will enroll 400 subjects. All three studies will randomize subjects to receive Cerimon's topical diclofenac sodium patch or placebo at a ratio of 1:1.

"Results from our Phase II acute ankle sprain study have demonstrated our topical diclofenac patch can deliver effective relief of acute pain due to mild-to-moderate musculoskeletal injuries without the side effects often associated with oral NSAIDs," stated James S. Shannon, M.D., Chief Executive Officer of Cerimon Pharmaceuticals. "Based on these data, we believe our diclofenac patch will be able to address the growing physician and patient interest in prescription therapies that can deliver safe, effective and convenient site-specific pain management."

Pain Market

Musculoskeletal pain is pain that affects the muscles, ligaments and tendons. Acute musculoskeletal injuries are common and can occur during sports activities, exercise or other physical activities. Acute musculoskeletal injuries generally require rapid treatment, which often includes the administration of anti-inflammatory drugs. Optimal topical treatment should relieve acute pain and reduce swelling in the injured area to restore normal movement. In addition, it should be safe and easy to administer.

<
'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Provide Proprietary Protein and Small Molecule Products for ... Stem (iPS) CellsLA JOLLA, Calif. and BOSTON, April ... and Stemgent, Inc. ... one-of-a-kind program to provide pharmaceutical and biotechnology companies ...
... 23 /PRNewswire-Asia/ -- Lotus Scarless Hair Transplantation,(International) Medical ... flagship transplant center on the prestigious Chang,an Avenue ... the first U.S. specialized,medical and plastics institution for ... With a floor area of 1,000 square ...
... drug delivery - , , MADISON, ... Roche Madison Inc. officially opened the doors to ... labs at the University of Wisconsin ... RNA Therapeutics group within Roche, the group,s research ...
Cached Biology Technology:Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijing's Prestigious Chang'An Avenue 2Roche Madison Moves to New Facility 2Roche Madison Moves to New Facility 3
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
(Date:7/24/2014)... different effects on different species of fish, according ... Bristol and Exeter which tested fish anti-predator behaviour. ... flying seagull predator model when exposed to additional ... minnows. , Lead author Dr Irene Voellmy ... levels in many aquatic environments have increased substantially ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... the eye where faces are concerned. With colleagues ... investigating the process of facial recognition, seeking to understand the ... when one person looks at another. His studies ... condition long known as prosopagnosia. Duchaine is trying to understand ...
... release is also available in Chinese on ... sun comes up, the ocean ground is radically cleaned. As ... into the water, the microalgae "Nitzschia cf pellucida" start their ... few micrometers, wrap themselves and their surroundings in a highly ...
... first of its kind book provides a practical guide ... and natural resources sciences. ,Analysis of Generalized Linear Mixed ... being released world-wide at an important time of change ... the design and analysis of mixed models for non-normally ...
Cached Biology News:Just another pretty face: Dartmouth professor investigates neural basis of prosopagnosia 2Just another pretty face: Dartmouth professor investigates neural basis of prosopagnosia 3Poisonous morning hygiene 2
Lipid Phosphate Phosphohydrolase 2...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: